If i was managing CSL, I would be running the ruler over AAH. They humanise antibodies for CSL so the immune system will not attack them and the antibodies can attack cancer cells. The lung cancer antibody AAH owns is of interest, but has not commenced human trials yet, due to start in 2010. Other AAH antibodies are closer to commercialisation all going well. I think it would be a good fit and further expansion into antibodies for CSL, though might be a bit early at the moment.
Anyway, my opinion, wish I'd bougt CSL earlier in the year! Don't have the money for it now :(
If i was managing CSL, I would be running the ruler over AAH....
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$302.04 |
Change
4.380(1.47%) |
Mkt cap ! $145.9B | |||
| Open | High | Low | Value | Volume |
| $300.00 | $302.49 | $299.34 | $178.5M | 592.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 285 | $302.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $302.10 | 67 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |